Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  243.04
-7.16 (-2.86%)
AAPL  269.77
-0.37 (-0.14%)
AMD  237.70
-18.63 (-7.27%)
BAC  53.29
+0.84 (1.60%)
GOOG  285.34
+0.59 (0.21%)
META  618.94
-17.01 (-2.67%)
MSFT  497.10
-10.06 (-1.98%)
NVDA  188.17
-7.04 (-3.61%)
ORCL  243.80
-6.51 (-2.60%)
TSLA  445.91
-16.16 (-3.50%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.